Eric Olman
Principal Scientist - Chemistry, Manufacturing & Controls Development Alnylam Pharmaceuticals
Eric Olmon is a Principal Scientist in CMC Development at Alnylam Pharmaceuticals, where he leads the development of manufacturing processes and analytical strategies for oligonucleotide therapeutics. With over 15 years of experience in nucleic acid research and biopharmaceutical development, he has extensive expertise spanning process development, analytical method development, nucleic acid chemistry, enzyme kinetics, and RNA-based technologies. Prior to joining Alnylam, Eric was an NIH Ruth L. Kirschstein NRSA Postdoctoral Fellow at Brown University and completed his PhD and postdoctoral research at the California Institute of Technology. His work focuses on advancing innovative nucleic acid therapeutics from development through commercialization
Seminars
- Explore how biocatalysis and enzyme engineering are enabling more efficient and scalable approaches to new modalities
- Discuss current challenges in enzymatic process development, including reaction optimization, selectivity, and process scalability
- Share perspectives on emerging opportunities for integrating enzymatic strategies into industrial biocatalysis manufacturing workflows
